UA83500C2 - Застосування дефібротиду як протипухлинного агента самостійно або в поєднанні з іншими протипухлинними агентами - Google Patents

Застосування дефібротиду як протипухлинного агента самостійно або в поєднанні з іншими протипухлинними агентами Download PDF

Info

Publication number
UA83500C2
UA83500C2 UAA200602374A UAA200602374A UA83500C2 UA 83500 C2 UA83500 C2 UA 83500C2 UA A200602374 A UAA200602374 A UA A200602374A UA A200602374 A UAA200602374 A UA A200602374A UA 83500 C2 UA83500 C2 UA 83500C2
Authority
UA
Ukraine
Prior art keywords
oei
azor
miyza
abai
kytyza
Prior art date
Application number
UAA200602374A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Лаура Ирис Ферро
Массимо Якобелли
Пол Ричардсон
Original Assignee
Джентиум Спа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джентиум Спа filed Critical Джентиум Спа
Publication of UA83500C2 publication Critical patent/UA83500C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UAA200602374A 2003-09-05 2004-08-27 Застосування дефібротиду як протипухлинного агента самостійно або в поєднанні з іншими протипухлинними агентами UA83500C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001714A ITMI20031714A1 (it) 2003-09-05 2003-09-05 Formazioni ad azione antitumorale.
US53934404P 2004-01-28 2004-01-28
PCT/EP2004/009723 WO2005023273A1 (en) 2003-09-05 2004-08-27 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents

Publications (1)

Publication Number Publication Date
UA83500C2 true UA83500C2 (uk) 2008-07-25

Family

ID=37064585

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200602374A UA83500C2 (uk) 2003-09-05 2004-08-27 Застосування дефібротиду як протипухлинного агента самостійно або в поєднанні з іншими протипухлинними агентами

Country Status (23)

Country Link
US (2) US8551967B2 (enExample)
EP (1) EP1660100B1 (enExample)
JP (1) JP4671962B2 (enExample)
KR (1) KR20060061367A (enExample)
CN (1) CN100490820C (enExample)
AT (1) ATE399558T1 (enExample)
AU (1) AU2004269896B2 (enExample)
BR (1) BRPI0414114A (enExample)
CA (1) CA2537226C (enExample)
DE (1) DE602004014787D1 (enExample)
DK (1) DK1660100T3 (enExample)
ES (1) ES2308223T3 (enExample)
IL (1) IL173785A0 (enExample)
IS (1) IS8334A (enExample)
IT (1) ITMI20031714A1 (enExample)
MX (1) MXPA06002489A (enExample)
NO (1) NO20061402L (enExample)
PT (1) PT1660100E (enExample)
RS (1) RS20060154A (enExample)
RU (1) RU2348413C2 (enExample)
UA (1) UA83500C2 (enExample)
WO (1) WO2005023273A1 (enExample)
ZA (1) ZA200601852B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070121001A (ko) * 2005-03-03 2007-12-26 젠티엄 에스피에이 신혈관 형성-의존성 종양 치료용 약학적 제제
EP1872787A1 (en) * 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP2103689A1 (en) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
KR102038357B1 (ko) 2012-06-22 2019-10-31 젠티엄 에스알엘 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
US10380734B2 (en) * 2017-02-27 2019-08-13 Aniket Bharat Parikh System, method and computer program product for security analysis of jewelry items
CN111132663A (zh) * 2017-08-03 2020-05-08 爵士制药爱尔兰有限公司 包含高浓度核酸的制剂
AU2019252790A1 (en) 2018-04-12 2020-10-15 Jazz Pharmaceuticals, Inc. Defibrotide for the prevention and treatment of cytokine release syndrome and neurotoxicity associated with immunodepletion
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
WO2021174039A1 (en) 2020-02-28 2021-09-02 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
US3899481A (en) 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
IT1043823B (it) 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US5977083A (en) 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
IT1252174B (it) 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
DE9202745U1 (de) 1992-03-02 1992-04-30 Howmedica Gmbh, 2314 Schoenkirchen Vorrichtung zum Verspannen von Wirbeln der menschlichen Wirbelsäule
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
AU754242B2 (en) * 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
WO1998054313A2 (en) 1997-05-30 1998-12-03 Mcgill University Dna methyltransferase genomic sequences and antisense oligonucleotides
US6177545B1 (en) 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de) 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
CA2377385A1 (en) * 1999-06-03 2000-12-14 Jessie L.S. Au Methods and compositions for modulating cell proliferation and cell death
PL366223A1 (en) * 2000-12-29 2005-01-24 Bio-Technology General Corp. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US6770753B2 (en) 2001-07-05 2004-08-03 The Trustees Of Columbia University In The City Of New York Phosphorothioate antisense heparanase oligonucleotides
AU2002353783A1 (en) 2001-09-24 2003-04-07 The Government Of The United States Of America As Represented By The Secretary Of The Department Of SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20050032882A1 (en) * 2002-03-06 2005-02-10 Sophie Chen Botanical extract compositions and methods of use
CN1304011C (zh) * 2002-05-31 2007-03-14 雷根斯堡大学医学院 保护性寡聚脱氧核糖核苷酸的制药用途
AU2003263764A1 (en) * 2002-07-01 2004-01-19 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US20060293256A1 (en) 2002-08-06 2006-12-28 Masateru Yamada Remedy or preventive for kidney disease and method of diagnosing kidney disease
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
KR20070121001A (ko) 2005-03-03 2007-12-26 젠티엄 에스피에이 신혈관 형성-의존성 종양 치료용 약학적 제제
EP1872787A1 (en) 2006-06-27 2008-01-02 Gentium S.p.A. Use of defibrotide for the inhibition of heparanase
EP1982722A1 (en) 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases

Also Published As

Publication number Publication date
PT1660100E (pt) 2008-10-14
AU2004269896A1 (en) 2005-03-17
US20060211646A1 (en) 2006-09-21
AU2004269896B2 (en) 2009-11-19
US20140005256A1 (en) 2014-01-02
KR20060061367A (ko) 2006-06-07
CA2537226A1 (en) 2005-03-17
CN100490820C (zh) 2009-05-27
EP1660100A1 (en) 2006-05-31
ATE399558T1 (de) 2008-07-15
MXPA06002489A (es) 2006-06-20
RU2348413C2 (ru) 2009-03-10
IS8334A (is) 2006-02-28
NO20061402L (no) 2006-03-28
ES2308223T3 (es) 2008-12-01
ZA200601852B (en) 2007-06-27
WO2005023273A1 (en) 2005-03-17
CN1845746A (zh) 2006-10-11
JP4671962B2 (ja) 2011-04-20
JP2007504194A (ja) 2007-03-01
BRPI0414114A (pt) 2006-10-31
RU2006109210A (ru) 2007-10-10
EP1660100B1 (en) 2008-07-02
IL173785A0 (en) 2006-07-05
ITMI20031714A1 (it) 2005-03-06
US8551967B2 (en) 2013-10-08
DK1660100T3 (da) 2008-11-10
RS20060154A (sr) 2008-08-07
CA2537226C (en) 2016-05-03
DE602004014787D1 (de) 2008-08-14

Similar Documents

Publication Publication Date Title
Wu et al. Collagen type II: From biosynthesis to advanced biomaterials for cartilage engineering
Saravanakumar et al. Biosynthesis and characterization of copper oxide nanoparticles from indigenous fungi and its effect of photothermolysis on human lung carcinoma
Alvarado-Gomez et al. Evaluation of anti-biofilm and cytotoxic effect of a gel formulation with Pluronic F-127 and silver nanoparticles as a potential treatment for skin wounds
Mojeiko et al. Combination of microneedles and microemulsions to increase celecoxib topical delivery for potential application in chemoprevention of breast cancer
Salvati et al. NO donors inhibit Leishmania infantum cysteine proteinase activity
Rigo et al. Characterization and evaluation of silver release from four different dressings used in burns care
Salim et al. Preparation, in-vitro and in-vivo evaluation of Rifampicin and Vancomycin Co-loaded transfersomal gel for the treatment of cutaneous leishmaniasis
EP2101724B1 (en) Administration of cellular extracts for rejuvenation
US10912834B2 (en) Topical formulations based on ionic species for skin treatment
Zahid et al. Antileishmanial agents co-loaded in transfersomes with enhanced macrophage uptake and reduced toxicity
Cheng et al. Green synthesis of chondroitin sulfate-capped silver nanoparticles: Characterization and surface modification
Jing et al. Ultrathin two-dimensional polydopamine nanosheets for multiple free radical scavenging and wound healing
CN112004531B (zh) 两部分的生成一氧化氮的局部组合物
US20050277694A1 (en) Topical compositions and methods for epithelial-related conditions
Tewari-Singh et al. Efficacy of glutathione in ameliorating sulfur mustard analog-induced toxicity in cultured skin epidermal cells and in SKH-1 mouse skin in vivo
Parwani et al. Antioxidant and iron-chelating activities of cyanobacterial exopolymers with potential for wound healing
Lima et al. Iron oxide nanoparticles show no toxicity in the comet assay in lymphocytes: A promising vehicle as a nitric oxide releasing nanocarrier in biomedical applications
KR102447039B1 (ko) 나노다이아몬드를 이용한 생리활성 물질의 가용화 방법
CL2022002150A1 (es) Moléculas de unión a antígeno anti-cd137 para su administración en el tratamiento contra el cáncer
Ichim et al. Synthesis and characterization of Colistin loaded nanoparticles used to combat multi-drug resistant microorganisms
Singpanna et al. Transdermal delivery, cytotoxicity and anti-melanogenic activity of p-chlorophenyl benzyl ether loaded-liposomes
Ge et al. Nanozyme doped chitosan hydrogel driven by glucose oxidase for dual regulation of ROS homeostasis and macrophage reprogramming in diabetic wound healing
KR101876282B1 (ko) 나노다이아몬드를 이용한 생리 활성물질의 경피 전달용 조성물 및 이의 제조방법
Cuypers et al. The effect of zinc doping on the cytocompatibility and antibacterial efficacy of hydroxyapatite nanoparticles for treatment of bone infection
Magnano et al. Evaluating the role of protective creams on the cutaneous penetration of Ni nanoparticles